Celsion Announces Ovarian Cancer Expert Presentation at Oppenheimer & Co. Investor Event
March 05, 2018 10:15 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., March 05, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced that Premal H. Thaker, M.D., M.S., Associate Professor of Obstetrics and Gynecology at the...
Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific Meeting
February 12, 2018 08:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation today announced that an abstract discussing the Company’s Phase III HEAT study evaluating ThermoDox® in combination with...
Celsion Corporation Provides Corporate Update and 2018 Outlook
January 18, 2018 08:00 ET
|
Celsion Corporation
Company Advances ThermoDox® for Treatment of Primary Liver Cancer Following Independent Data Monitoring Committee’s Unanimous Recommendation to Continue Phase III OPTIMA Study OPTIMA Study...
Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer
January 04, 2018 08:00 ET
|
Celsion Corporation
GEN-1 to Enter the Clinic in Mid-2018 Following a Phase IB Trial Which Demonstrated 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients...
Celsion Announces Publication of the Study of ThermoDox® + Ultrasound, “TARDOX Study Protocol” in the Journal of Therapeutic Ultrasound
November 20, 2017 08:00 ET
|
Celsion Corporation
Collaboration with University of Oxford to Execute a Clinical Trial Using Focused Ultrasound and ThermoDox® for Primary and Metastatic Liver Cancer Presentation of TARDOX Study Phase I Findings at...
Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business Update
November 14, 2017 08:00 ET
|
Celsion Corporation
Recent Minimally Dilutive Financings Substantially Strengthen Balance Sheet and Provide Runway to Significant Clinical Milestones for ThermoDox® and GEN-1 Clinical Programs Company to Hold Conference...
CORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer
November 13, 2017 19:23 ET
|
Celsion Corporation
Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian Cancer GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018...
Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer
November 13, 2017 17:15 ET
|
Celsion Corporation
Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian Cancer GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018...
Celsion Corporation to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017
November 07, 2017 09:00 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Celsion Corporation Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
October 27, 2017 09:10 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the “Company”) (NASDAQ:CLSN) today announced the pricing of an underwritten offering of 2,640,000 shares of its common...